CHRS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CH

Volume

849.75K

Next Earnings

November 5th

Loading chart

CH

CHRSCoherus Oncology, Inc. Common Stock

CHRS

Pay with—

Available Balance0.00

CH

Mkt Cap

$162.2M

Volume

849.75K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026Coherus Oncology announced it will release second quarter 2026 financial results on August 5, 2026, followed by a conference call at 5:00 p.m. EDT. The company will discuss financial performance and provide a business update on its oncology pipeline, including its approved PD-1 inhibitor LOQTORZI and mid-stage clinical candidates.GlobeNewswire Inc. · Jul 22, 2026

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)Coherus Oncology and Zumutor Biologics announced a Phase 1 clinical collaboration to evaluate ZM008, an anti-LLT1 monoclonal antibody, in combination with LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, in patients with various solid tumors. The trial will enroll up to 45 patients and aims to evaluate safety, tolerability, and identify biomarkers for personalized therapies. Both companies retain commercial rights to their respective compounds.GlobeNewswire Inc. · Jun 23, 2026

Coherus Oncology, Inc. Announces Closing of Public Offering of Common StockCoherus Oncology completed a public offering of 28.6 million shares at $1.75 per share, raising approximately $50.1 million in gross proceeds. The company plans to use the funds to support commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development of pipeline candidates, and for general corporate purposes. The offering was led by healthcare investors including Janus Henderson, HBM Healthcare Investments, and Samsara BioCapital.Benzinga · Feb 17, 2026

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common StockCoherus Oncology priced an underwritten public offering of 28.6 million shares at $1.75 per share, generating approximately $50.1 million in gross proceeds. The company plans to use the funds to support commercialization of its PD-1 inhibitor LOQTORZI, advance clinical development of pipeline candidates, and for general corporate purposes. The offering is expected to close on February 17, 2026.GlobeNewswire Inc. · Feb 13, 2026

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs OfficerCoherus Oncology announced the appointment of Arvind Sood as Chief Strategy and Corporate Affairs Officer, focusing on advancing innovative cancer therapeutics and driving revenues for LOQTORZI®.GlobeNewswire Inc. · Nov 6, 2025

Coherus Announces Repurchase of Approximately $170 Million of Convertible NotesCoherus BioSciences announced it will repurchase $170 million of its convertible notes and divest its UDENYCA franchise to Intas Pharmaceuticals. The company plans to repurchase the remaining $60 million of convertible notes after the divestiture closes.GlobeNewswire Inc. · Apr 1, 2025

Hepatic Tumor Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ Companies Working in the DomainThe hepatic tumor market is driven by the increasing incidence of liver cancer, advancements in treatment options, and the growing emphasis on personalized medicine and combination therapies. The pipeline comprises 75+ companies working on 75+ pipeline therapies, with several promising candidates in different phases of clinical trials.GlobeNewswire Inc. · Jul 30, 2024

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction– Transaction aligns with Coherus’ strategic focus on oncology – – Transaction aligns with Coherus’ strategic focus on oncology –GlobeNewswire Inc. · Jun 27, 2024

Pfizer: Seriously Undervalued At Peak PessimismPfizer's impressive financial results and promising clinical trials make it an undervalued asset in the pharmaceutical industry.Seeking Alpha · Jun 23, 2024

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingCHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumorsGlobeNewswire Inc. · May 23, 2024

to start trading

CH

CHRSCoherus Oncology, Inc. Common Stock

CHRS

Pay with—

Available Balance0.00

Your PositionYou don't own any CHRS yet.

Related Tickers

Earnings